An Initial Study of AZD7325 in Adults With Fragile X Syndrome

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This study will investigate the safety, tolerability and blood pharmacodynamics of treatment with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers during treatment.
Epistemonikos ID: 391767534e13a706501a82cbc75c3031ecabd8b6
First added on: May 20, 2024